KLK5 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

19 results for “KLK5”

Trials

Polymorphisms in ENAM, AMBN, and KLK4 Contribute to DCS.

204 participants · First posted Apr 3, 2024

Active, not recruiting

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

216 participants · First posted May 24, 2021

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

100 participants · First posted Jun 20, 2016

Drugs

Anti-KLK5/KLK7 bispecific antibody(Genentech)

ALK5 inhibitors (cancer)

KLK3 inhibitors(Merck)

News

Triveni Bio Initiates Phase 2 Trial of Novel Anti-KLK5/7 Antibody TRIV-509 for Atopic Dermatitis

Triveni Bio Initiates Phase 1 Trial of Dual-Target Bispecific Antibody TRIV-573 for Atopic Dermatitis

Triveni Bio Initiates First-in-Human Trial of TRIV-509 for Atopic Dermatitis, Targeting Novel Kallikrein Pathway

Page 1 of 2